#
Title
1

Anti-CD20 Therapy Safety and Outcomes in Pregnancy

2

Neuronal Antibodies in Atypical Parkinsonism Clinical Screening Study

3

Anticoagulation in Atrial Fibrillation with Prior Intracranial Haemorrhage

4

Predictors of Fatigue Trajectories in Multiple Sclerosis

5

Diagnosis of Purely Lower Motor Neuron Syndromes

6

Quality of Care Delivered by International Medical Graduates in Canada

7

Neuropsychiatric Risks of Anti-Seizure Medications

8

Neurostimulation for Drug-Resistant Epilepsy

9

Multidisciplinary Care for Fragile X-Associated Tremor/Ataxia Syndrome

10

Predicting Parkinson’s Disease Motor Progression Using Digital and Clinical Data

11

Midlife Vitamin D Levels and Future Brain Tau Accumulation

12

Myasthenia Gravis Risks During Pregnancy and Postpartum Periods

13

Lyme Disease: Epidemiology, Diagnosis, and Management in North America

14

West Nile Virus: A Comprehensive Clinical and Epidemiological Framework

15

Multiple System Atrophy: Multimodal Biomarkers and Clinical Phenotypes

16

IV Fosphenytoin for Acute Trigeminal Neuralgia Exacerbations

17

Drugs for Migraine Prophylaxis

18

Intrathecal Mesenchymal Stem Cells in Progressive MS: The SMART-MS Trial

19

Neurologic Adverse Events from Immune Checkpoint Inhibitors

20

Anti-KLHL11 Encephalitis

21

Sleep Neurology: Pearls and Pitfalls for the Practising Neurologist

22

Tavapadon as Adjunctive Therapy for Parkinson Disease - TEMPO-3 Trial

23

Identifying Autoimmune Encephalitis in Rapidly Progressive Dementia

24

Heterogeneity in Primary CNS Vasculitis

25

Neurological Involvements of Multiple Myeloma: A Comprehensive Clinical Review

26

2026 European Guidelines for Management of Aneurysmal Subarachnoid Haemorrhage

27

Neurological Assessment and Management of Autonomic Failure

28

Intracranial Arterial Dolichoectasia: A Comprehensive Review

29

N-Acetylcysteine in Ischemic Stroke: A Systematic Review

30

Thiamin and Folic Acid for Cognitive Impairment in Hemodialysis Patients

31

Advances in the Treatment of Autoimmune Nodopathy

32

Advances in Guillain-Barré Syndrome: Diagnosis, Biomarkers, and Management

33

GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

34

Anti-Amphiphysin Antibody Positive Autoimmune Syndrome

35

Shingles Vaccination and Reduced Dementia Risk

36

Approach to Asymptomatic HyperCKemia - EAN Guidelines

37

Predictive T-Cell Biomarkers for Checkpoint Inhibitor Response in PML

38

Practical Strategies for SCIg Maintenance Therapy in CIDP Patients

39

Treatment of Spinal Cavernous Malformations: A Systematic Review

40

Augmenting Diagnostic Yield From Genomic Testing in Neurological Diseases

41

Spinal and Bulbar Muscular Atrophy: Pathogenesis and Therapeutic Horizons

42

Phase 3 Trial of Brepocitinib in Dermatomyositis

43

Are Patients with Essential Tremor at Increased Risk of Parkinson's Disease?

44

Efficacy of Hyperbaric Oxygen in Neurological Disorders

45

Recent Advances in Targeted Therapies for Adult Gliomas

46

Modafinil for Excessive Daytime Sleepiness in Narcolepsy: A Meta-Analysis

47

The European Medicines Agency's Assessment of Lecanemab and Donanemab for Alzheimer’s Disease

48

The Vital Role of PET/CT in NF1 Cancer Surveillance

49

A Diagnostic Assay for Multiple Sclerosis Based on EBV

50

Radiologically Isolated Syndrome: A Practical Clinical Guide

51

Stenting vs. Shunting for Sight-Threatening Intracranial Hypertension

52

AI-Driven Biomarkers in Neurology: A Narrative Review

53

Pompe Disease - Advances in Diagnosis and Management

54

Hallmarks of Secondary Headaches

55

Del-desiran Therapy for Myotonic Dystrophy Type 1

56

Long-Term Efficacy and Safety of Tofersen in SOD1-ALS Patients

57

Movement Disorders and Oculomotor Abnormalities in Whipple's Disease

58

Acute Disseminated Encephalomyelitis (ADEM): Review

59

A refresher on abnormal spontaneous EMG activities

60

A Review of Posterior Reversible Encephalopathy Syndrome (PRES)

61

General neurologists guide for diagnosis of atypical parkinsonian disorders

62

Refractory, intensive care–dependent NMDAR encephalitis

63

LRP4 Antibodies in Suspected Myasthenia Gravis Diagnosis

64

Autoimmune encephalitis during the COVID-19 pandemic

65

Dermatomyositis: Modern Diagnostic Paradigms

66

The HTLV-1 Neurological Complex: Beyond Myelopathy

67

Alpha-Lipoic Acid Efficacy in Managing Diabetic Polyneuropathy Symptoms

68

Etiological Screening Strategies for Small Fiber Neuropathy

69

Tenecteplase in acute central retinal artery occlusion, a phase 3 Clinical Trial

70

How to use blood-based biomarkers to diagnose Alzheimer’s disease

71

Brief Review - 2026 Guidelines for Early Management of Acute Ischemic Stroke

72

Multifocal Motor Neuropathy: Clinical Features, Diagnosis, and Treatment Bibliography

73

Stiff Person Syndrome: Clinical Spectrum, Diagnosis, and Management

74

Management of Dementia with Lewy Bodies, A Review

75

Seronegative Autoimmune Encephalitis

76

Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord

77

Distinguishing Vestibular Vertigo from Posterior Stroke

78

2025 In Review - MS and Autoimmune CNS Disorders

79

2025 In Review - Epilepsy

80

2025 In Review - Stroke and Neurovascular Disorders

81

2025 In Review - Movement Disorders

82

2025 In Review - Neuromuscular Disorders

83

GLP-1 Receptor Agonists: Efficacy, Safety, and Neurological Frontiers

84

Treating psychiatric comorbidities in patients with epilepsy.

85

The prognosis and treatment outcomes for individuals with focal epilepsy

86

Global surge of early-onset Parkinson’s disease (EOPD) 

87

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES)

88

Long-term outcomes of seizures and epilepsy in patients with untreated cerebral cavernous malformations

89

Phenotype-Genotype Correlations in Myelin Protein Zero (MPZ) Variants

90

Cardiac Involvement in Myotonic Dystrophy Type 1 and 2

91

Rituximab Therapy for Resistant Myasthenia Gravis

92

Advances in Treatment of Myasthenia Gravis

93

Peripheral Neuropathy: A Comprehensive Review

94

Diagnostic Controversies in Chronic Inflammatory Demyelinating Polyneuropathy

95

Early Use of Rituximab in New-Onset Generalized Myasthenia Gravis: RINOMAX Trial

96

CAR-T cell therapy, neurological risks and potential use

97

Active Inference Model of Functional Neurological Disorder

98

Are COVID-19, RSV, and Influenza vaccines safe and effective?

99

Outcome Measures for Adult Becker Muscular Dystrophy Progression

100

2025 ILAE 2025 updated seizure classification

101

Myasthenia Gravis 2025 Updated Management Guidelines from the Association of British Neurologists

102

Iatrogenic Cerebral Amyloid Angiopathy (CAA) and CAA related inflammation (CAA-ri)

103

Early Tirofiban After Thrombolysis for Ischemic Stroke (ASSET-IT trial)

104

Friedreich’s ataxia - A Comprehensive Look

105

CADASIL Unmasked

106

TTR Familial Amyloidosis Genotype-Phenotype Correlation

107

Spinal Bulbar Muscular Atrophy: Canadian Best Practice Recommendations

108

2025 Revised Criteria for Vascular Cognitive Impairment

109

Idiopathic Normal Pressure Hydrocephalus: Incidence, Progression, Diagnosis and Treatment

110

Glycine Receptor Antibody Associated Progressive Encephalomyelitis Clinical Outcomes (PREM)

111

Neurological complications of drug misuse

112

Minimally invasive surgery for intracerebral hemorrhage

113

A blood test to distinguish Parkinson's disease and Dementia with Lewy bodies

114

Navigating Postanoxic Status Epilepticus

115

Migraine Prevention Review: Therapies, Efficacy, and Safety

116

Using serum NFL and antibody titer to monitor disease activity in CASPR2/LGI1 autoimmune encephalitis

117

Peripheral blood monocytes can predict impending relapses and disability worsening in MS

118

Late Effects of Traumatic Brain Injury

119

Oseltamivir Reduces Pediatric Neuropsychiatric Events During Influenza

120

Health Anxiety in Neurological Settings

121

Laser interstitial thermal therapy for mesial temporal lobe epilepsy

122

Myasthenia Gravis Autoantibody Heterogeneity and Therapeutic Implications

123

VCP Multisystem Proteinopathy

124

Updated AAN Guidelines on prolonged disorders of consciousness

125

Psychiatric comorbidities are an independent risk factor for unfavorable outcomes in Autoimmune Encephalitis

126

Timing of Anticoagulation for Stroke and Atrial Fibrillation

127

Treating Small Vessel CNS Vasculitis: Early Intervention and Remission

128

Neurofilament Light Chain Assays in MS Management

129

Nucleoside reverse transcriptase inhibitor use and reduced risk of Alzheimer’s disease

130

Lipoprotein a and Stroke Recurrence: A Systematic Review

131

Serum NFL as a biomarker for CIDP Diagnosis and Treatment

132

Upadacitinib for Giant-Cell Arteritis, SELECT-GCA Trial Results

133

Assessing Functional Motor Weakness: A Practical Guide

134

Treating Neuropsychiatric Symptoms in Parkinson's Disease

135

Rituximab Use in Anti-NMDAR Antibody-Mediated Encephalitis Relapse Prevention

136

Understanding Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders

137

Repeat Expansion Disorders in Neurology

138

Neurological IgG4-Related Disease: Diagnosis and Management

139

Long-Term Ravulizumab Efficacy and Safety in Generalized Myasthenia Gravis

140

The Second European Carotid Surgery Trial (ECST-2)

141

Inebilizumab Trial in Myasthenia Gravis

142

Brain MRI as prognostic factor in Anti NMDA Encephalitis

143

Efgartigimod Efficacy and Safety in CIDP - ADHERE and ADHERE+ Trials

144

Telitacicept Shows Strong Efficacy for Generalized Myasthenia Gravis

145

C5 vs FcRn inhibitors for generalized myasthenia gravis

146

MMF for anti-NMDA antibody maintenance

147

European Guidelines for Assessment and Management of Neurogenic Bladder

148

ADVANCE CIDP -IVIG Clinical Trial

149

Multifocal Motor Neuropathy - A Comprehensive Review

150

Bone marrow transplantation for MS, ECTRIMS Recommendation

151

Do glucose lowering drugs prevent dementia?

152

Serum NfL as a Diagnostic and Prognostic ALS Biomarker

153

Stress and cryptogenic stroke in young adults

154

Using AI Vision in Neurology

155

European Guidelines on PET imaging for brain metastasis

156

Pyridostigmine for Orthostatic Hypotension

157

MoCA vs MMSE for Frontotemporal Dementia

158

Prognosis of Postanoxic Status Epilepticus

159

Idiopathic intracranial hypertension - diagnosis

160

rTMS Trial for Cognitive Impairment in ALS

161

Rozanolixizumab in Generalized Myasthenia Gravis - OLE

162

CSF-Serum Free Kappa Light Chain Index - Optic Neuritis Diagnosis

163

ABN Guidelines on Multiple Sclerosis Disease-Modifying Treatment

164

Neurological complications of immune checkpoint inhibitors

165

TMPN Trial in ALS

166

A Practical Approach to the Diagnosis of Neuropathies

167

Therapeutics in Inflammatory Muscle Diseases

168

Treatment of Cluster Headaches

169

Clinical Trial of Zilucoplan in ALS

170

Is Multiple Sclerosis a Virus-Induced Gliopathy?

171

DDPX Antibody Associated Encephalitis - A Review

172

Antidepressant use and cognitive decline in patients with dementia: a national cohort study

173

Cost of New Neurologic Medications

174

rTMS and Aphasia Therapy Post-Stroke, a Clinical Trial

175

Periodic EEG Patterns

176

Acceptance and Commitment Therapy

177

Endovascular therapy versus best medical care for acute ischemic stroke with distal medium vessel occlusion

178

Exenatide in Parkinson’s disease phase 3 trial

179

No long‑term benefits from resistance training on brain grey matter volumes in active older adults at retirement age

180

Tirofiban Efficacy in Stroke

181

International Consensus Guidance for Managing Glucocorticoid-Related Neuromuscular Complications

182

Consensus Statement on Continuous EEG in Critically Ill Patients

183

AI-Optimized Anti-Seizure Treatment and EEG in Brain Injury

184

MOG Antibody Testing in Clinical Practice

185

LUMINESCE A phase 3 trial clinical trial of satralizumab for generalized myasthenia gravis

186

Lipid Variability and Cognitive Decline in Older Adults

187

Blood Biomarkers and MS Diagnosis

188

Long-Term Ocrelizumab Treatment for Early-Stage Relapsing MS

189

The Spectrum of Genetic Risk in Alzheimer's Disease

190

Central Nervous System Manifestations in Sjögren's Disease

191

Intravenous Thrombolysis for Minor Stroke - A Systematic Review and Meta-analysis

192

Cancer risk in multiple sclerosis patients and DMT

193

Neurogenic Orthostatic Hypotension in Parkinson's Disease

194

Cognitive decline after heart failure

195

Friedreich Ataxia: A 30-Year Retrospective

196

Breaking Bad News in ALS/MND: The A-L S-PIKES Protocol

197

Plasma Neurofilaments as ALS Biomarkers

198

APOE's Role in Cerebral Amyloid Angiopathy

199

Intra-arterial Tenecteplase After Posterior Circulation Recanalization - ATTENTION-IA trial

200

WHO Classification of Central Nervous System Tumors, Fifth Edition - A flashback to 2021

201

Tele-EEG for Critically Ill Patients: A Multicenter RCT

202

Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study

203

Autoimmune Nodopathies and IgG4 Antibodies in Neurology

204

Anti-IgLON5 Disease: A Decade of Discovery and Unanswered Questions

205

SAHARA Trial: Transfusion Strategies in Aneurysmal Subarachnoid Hemorrhage

206

CRISPR-Cas9 Gene Editing for ATTR Cardiomyopathy

207

Introduction to Weekly Deep Dive Neurology Podcast

208

Memantine in Amyotrophic Lateral Sclerosis

209

Rituximab for Idiopathic Inflammatory Myositis: A Systematic Review and Meta-analysis

210

Vutrisiran for ATTR cardiomyopathy

211

Long-Term Safety of fSCIG for CIDP Maintenance Therapy

212

Neurofilament Light Chain and GFAP in Mood and Anxiety Disorders

213

Efficacy and Safety of IVIG Maintenance Therapy in Generalized Myasthenia Gravis

214

Anticoagulation strategy for patients presenting with ischemic strokes while using a direct oral anticoagulant:

215

Early Atogepant Efficacy in Migraine Prevention

216

2024 AASM Clinical Practice Guideline: Restless Legs Syndrome and PLMD Treatment